Adamas announces changes to its board of directors with the appointment of spyros papapetropoulos and the retirement of ivan lieberburg

Emeryville, calif., nov. 23, 2020 (globe newswire) -- adamas pharmaceuticals, inc. (nasdaq: adms) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of spyros papapetropoulos, md, phd, to its board of directors. spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held r&d and scientific leadership roles at acadia, cavion, teva, pfizer, allergan, and biogen. additionally, adamas announced the retirement of ivan lieberburg, md, phd from the adamas board.
ADMS Ratings Summary
ADMS Quant Ranking